Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis

Zhou, JD; Lee, S; Lakhani, I; Yang, L; Liu, T; Zhang, YH; Xia, YL; Wong, WT; Bao, KKH; Wong, ICK; Tse, G; Zhang, QP

Zhang, QP (通讯作者),Univ Oxford, Nuffield Dept Med, Oxford, England.;Tse, G (通讯作者),UK Collaborat, Cardiooncol Res Unit, Cardiovasc Analyt Grp, Hong Kong, Peoples R China.;Tse, G (通讯作者),Tianjin Med Univ, Tianjin Inst Cardiol, Dept Cardiol, Tianjin Key Lab Ion Mol Funct Cardiovasc Dis,Hosp, Tianjin 300211, Peoples R China.;Tse, G (通讯作者),Kent & Medway Med Sch, Canterbury, Kent, England.;Zhang, QP (通讯作者),City Univ Hong Kong, Sch Data Sci, Hong Kong, Peoples R China.

CARDIO-ONCOLOGY, 2022; 8 (1):

Abstract

Background Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major c......

Full Text Link